Boehringer Ingelheim (BI) signed a USD 1 billion deal with Re-Vana Therapeutics on 28 July to develop sustained-release ophthalmic therapies using Re-Vana's light-activated drug delivery technology. The platform enables biodegradable intraocular implants that release drugs for 3 to 12 months via a single injection, potentially transforming treatment for conditions like age-related macular degeneration (AMD). Re-Vana's lead candidate, an anti-VEGF implant, is in Phase II/III trials with data supporting 6-month dosing intervals.

The agreement covers up to three programs, with BI handling clinical development and commercialisation. Re-Vana's patented "one-step photopolymerisation" technology preserves protein stability while allowing customisable release profiles. The deal marks Boehringer's push into ophthalmology, where it currently has four early-stage candidates. Competitors like Novartis and Roche are also advancing long-acting ocular implants, with Novartis's ranibizumab implant achieving quarterly dosing in Phase III.

According to PharmCube's NextBiopharm® database, BI's ophthalmology program includes antibody modalities such as mAbs, BsAbs and antibody fragments. Click here to request a free trial for NextBiopharm®.

Source:
https://www.vbdata.cn/1519032886